Reaction
Systemic Lupus Erythematosus Rash reporting signals
As of the last recalculation, Systemic Lupus Erythematosus Rash appears in 792 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS (PRR 180.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Diltiazem Hydrochloride Extended-Release Tablets | 71 | 180.0 | 181.2 |
| Cortisone Acetate | 75 | 176.2 | 177.3 |
| Naproxen Sodium Tablet, Coated | 69 | 146.6 | 147.4 |
| Naproxen Sodium, Coated Tablets | 69 | 146.6 | 147.4 |
| Naproxen Sodium 220Mg | 69 | 146.4 | 147.1 |
| Esomeprazole Magnesium Capsule, Delayed Release | 67 | 132.5 | 133.1 |
| Esomeprazole Magnesium Delayed Release Capsules | 67 | 132.5 | 133.1 |
| Esomeprazole Magnesium Dihydrate | 67 | 131.9 | 132.5 |
| Desoximetasone | 78 | 119.2 | 119.7 |
| Risedronate Sodium | 96 | 92.2 | 92.5 |
| Belimumab | 76 | 69.7 | 69.8 |
| Diltiazem Hydrochloride | 78 | 65.6 | 65.8 |
| Terbinafine Hydrochloride | 13 | 39.1 | 39.1 |
| Naproxen | 89 | 33.4 | 33.5 |
| Leflunomide | 114 | 33.3 | 33.3 |
| Esomeprazole | 71 | 33.0 | 33.0 |
| Tocilizumab | 112 | 29.9 | 29.9 |
| Certolizumab Pegol | 113 | 29.4 | 29.4 |
| Golimumab | 85 | 29.1 | 29.1 |
| Meperidine Hydrochloride | 10 | 28.9 | 28.9 |
| Abatacept | 105 | 22.8 | 22.8 |
| Naproxen Sodium | 104 | 21.9 | 21.9 |
| Voclosporin | 5 | 15.2 | 15.2 |
| Tofacitinib | 92 | 14.7 | 14.7 |
| Etanercept | 172 | 9.4 | 9.4 |